These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22611059)

  • 21. Characteristics of an ideal rotavirus vaccine.
    Reisinger KS; Block SL
    Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
    J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants.
    Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings?
    Centenari C; Gurgel RQ; Bohland AK; Oliveira DM; Faragher B; Cuevas LE
    Vaccine; 2010 Jun; 28(25):4162-8. PubMed ID: 20417608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
    Wu CL; Yang YC; Huang LM; Chen KT
    Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global impact of rotavirus vaccines.
    Tate JE; Patel MM; Steele AD; Gentsch JR; Payne DC; Cortese MM; Nakagomi O; Cunliffe NA; Jiang B; Neuzil KM; de Oliveira LH; Glass RI; Parashar UD
    Expert Rev Vaccines; 2010 Apr; 9(4):395-407. PubMed ID: 20370550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rotavirus vaccination in developing countries.
    Babji S; Kang G
    Curr Opin Virol; 2012 Aug; 2(4):443-8. PubMed ID: 22698800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introducing the rotavirus vaccine in the UK.
    Paul SP; Basude D
    Nurs Times; 2013 Jun 26-Jul 2; 109(25):12-3. PubMed ID: 23905294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outstanding challenges for rotavirus vaccine introduction in low-income countries--a systematic review.
    Ustrup M; Madsen LB; Bygbjerg IC; Konradsen F
    Dan Med Bull; 2011 Oct; 58(10):A4323. PubMed ID: 21975154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease and economic burden of rotavirus diarrhoea in India.
    Tate JE; Chitambar S; Esposito DH; Sarkar R; Gladstone B; Ramani S; Raghava MV; Sowmyanarayanan TV; Gandhe S; Arora R; Parashar UD; Kang G
    Vaccine; 2009 Nov; 27 Suppl 5():F18-24. PubMed ID: 19931713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should rotavirus vaccines be included in the national immunization program of a small developed country?
    Milne R; Grimwood K
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):401-4. PubMed ID: 19817522
    [No Abstract]   [Full Text] [Related]  

  • 34. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?
    Patel MM; Glass R; Desai R; Tate JE; Parashar UD
    Lancet Infect Dis; 2012 Jul; 12(7):561-70. PubMed ID: 22742639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease.
    Harris JP; Jit M; Cooper D; Edmunds WJ
    Vaccine; 2007 May; 25(20):3962-70. PubMed ID: 17395343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece.
    Syriopoulou V; Kafetzis D; Theodoridou M; Syrogiannopoulos GA; Mantagos S; Trimis G; Mavrikou M; Konstantopoulos A
    Acta Paediatr; 2011 May; 100(5):732-9. PubMed ID: 21223372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.
    Kotsopoulos N; Connolly MP; Postma MJ; Hutubessy RC
    Vaccine; 2013 Nov; 31(46):5430-4. PubMed ID: 24055088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
    Rheingans R; Atherly D; Anderson J
    Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of vaccine on rotavirus disease in the pediatric population.
    Dennehy PH
    Curr Opin Pediatr; 2012 Feb; 24(1):76-84. PubMed ID: 22189398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.